Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation

R. Iannotta a,*, M. Celentano a, S. Marotta a, C.M. Pedata a, C. Riccardi a, I. Migliaccio a, A. Viola b, S.M. Muggianu a, C. Falco c, D Bovenzi c, F. Ferrara b, A. Picardi a,d

a Stem Cell Transplant Program, AORN Cardarelli, Naples, Italy
b Hematology, AORN Cardarelli, Naples, Italy
c Transfusion Medicine Service, AORN Cardarelli, Naples, Italy
d Dep. of Biomedicine and Prevention, Tor Vergata University, Rome, Italy

1. Introduction

About 30% of AML patients harbor mutation in the FLT3 gene, which is involved in the proliferation and normal differentiation of haematopoietic stem cells. More in detail, these mutations involve the juxta-membrane region of the receptor (duplications in frame - ITD) or may be point mutations of the tyrosine kinase domain (TKD), with the effect of a receptor’s constant activation in absence of ligand. Currently, new target therapies are available for these patients, such as the oral selective FLT3 inhibitor Gilteritinib, currently approved for the treatment of adults with relapsed/refractory FLT3 AML as well as Midostaurin for newly diagnosed patients in combination with chemotherapy [1]. Recurrence of AML can also occur at extramedullary level potentially involving different organs and most frequent localization is the skin, with cumulative incidence of 5–12% [1,2].

Currently, few cases [1,2,3] of extramedullary relapse of AML FLT3 treated with FLT3 inhibitors are reported, in particular after the first or second allogeneic HSCT [3,4,5]. We report here the case of a FLT3 AML patient with bone marrow and mammary extramedullary relapse, after 1st and 2nd allogeneic HSCT, respectively, and successfully treated with Gilteritinib in both cases.

2. Case presentation

In April 2019, a female patient, 35 years old, received diagnosis of NPM1 and FLT3-ITD positive AML, in absence of cytogenetic alterations. The patient presented with hyperleukocytosis, anemia, thrombocytopenia (blood count at diagnosis revealed WBC 175,94 × 10³/μL) and disseminated intravascular coagulation (DIC). The patient was classified as high-risk according to ELN criteria. In addition, bilateral hemovitreus and left retinal detachment were present with subsequent loss of bilateral vision. The first induction chemotherapy consisted of 3 + 7 schedule (cytarabine + daunorubicin) combined with midostaurin, according to current standard of care, with no hematological response. The subsequent salvage chemotherapy included IDA-FLA protocol (fluidarabine 25 mg/m² d 1–2–3–4–5 + cytarabine 200 mg/m²2 d 1–2–3–4–5 + idarubicin 10 mg/m²2 d 1–3) with the achievement of morphological bone marrow complete remission (CR); minimal residual disease (MRD) evaluation by immunophenotype revealed 0.6% contamination in the bone marrow. In this phase, central nervous system involvement was excluded by cerebrospinal fluid morphologic and immunophenotypic examination. Consolidation therapy consisted of 1 cycle of FLA scheme (fluidarabine 25 mg/m²2 d 1–2–3–4–5 and cytarabine 2.000 mg/m²2
blood count showed leucopenia, anemia and thrombocytopenia whereas FLT3 inhibitor was withdrawn and a life-saving persisting bone marrow blasts percentage of 10%. For this reason, the marrow blast cells from 84% to 10%.

3191 copies of NPM1. Subsequently, the patient started oral Gilteritinib documented 84% of blast cells with the same markers.

The bone marrow morphologic and immunopenotypic analysis IP the bone marrow aspiration showed a morphological relapse with a loss of donor chimerism (quantitative donor chimerism) on day 15 and + 20 for ANC and PLTS, respectively [5]. No early severe complications occurred and quantitative chimerism, evaluated through the QPCR method (indeqRT-PCR) showed full donor status on day +30 and +60. The monitoring of MRD was carried out with the evaluation of the mutational status of the NPM1 gene in peripheral and marrow blood [4,6].

On day + 90 after the 1st allogeneic HSCT procedure, the peripheral blood count showed leucopenia, anemia and thrombocytopenia whereas the bone marrow aspiration showed a morphological relapse with a loss of donor chimerism (quantitative donor chimerism = 23%). Moreover, the bone marrow morphologic and immunopenotypic analysis IP documented 84% of blast cells with the same markers’ expression as at diagnosis (CD34+/−,CD117+/−,CD33+/−,CD13+/−,CD10+/−,CD7+/−,CD45+/−) and 3191 copies of NPM1. Subsequently, the patient started oral Gilteritinib at dose of 120 mg/day, as compassionate use, with reduction of bone marrow blast cells from 84% to 10%

Gilteritinib was well tolerated for 1 month until the occurrence of posttransplant check (corresponding at day +90 after 1st autologous stem cell transplantation). The main complications after the 2nd allogeneic HSCT were represented by acute and chronic GVHD [6,7].

Chimerism status and MRD evaluation after the 1st and the 2nd allogeneic HSCT are reported in Table 1 and 2, respectively.

On day + 40 after the second allogeneic procedure, acute cutaneous grade III GVHD, involving 90% of the body surface, occurred and high dose of 6-Metilprednisone (2 mg/kg) was promptly started. Due to the progression of skin aGVHD into bullos erythoderma and appearance of grade I liver GVHD, a second line therapy with infliximab at 10 mg/kg was started in association with ancillary cutaneous treatment based on heterologous platelet gel local application [7,8]. Given the gradual resolution of the skin and liver GVHD after 2 courses of Infliximab, slow steroid tapering was performed [6,7].

On day + 90 after the 2nd allogeneic HSCT, bone marrow aspiration showed morphological CR, full donor chimerism (99.93%) and NPM1 of 0.003 copies with a reduction of six logarithms compared to the pretransplant check (corresponding at day +90 after 1st autologous HSCT procedure).

After a few months, the patient developed severe chronic GVHD, involving skin and lung, that was treated with steroid and FAM protocol (montelukast, azithromycin, and fluticasone) achieving partial cutaneous response and a significant FEVI recovery. On day + 120 after the 2nd allogeneic SCT, the follow up confirmed morphological CR and full donor chimerism at bone marrow aspiration associated with NPM1 of 0.023 copies. However, clinical occurrence of three right breast lesions was highlighted by ultrasound. PET /TC (positron emission tomography) with a SUV uptake of 6.8,7.8 and 2.6, respectively. Stereotactic biopsy of the 3 mammalian nodules was performed. The histological assay confirmed the suspected relapse of AML C.D34+/− /CD68+/− /Ckit+/− /LCA+ /CD33+ and focally CD34+ cells occasionally positivity for myeloperoxidase and negativity for pancytokeratin. Breast presence of FLT3 ITD was also documented by PCR and agarose gel electrophoresis (Kit LeukoStrat FLT3 Mutation Assay- Gel detection, Invivoscribe).

On day + 400 after the 2nd allogeneic HSCT, while on treatment Gilteritinib, QTC lengthening was documented with subsequent withdrawn of the FLT3 inhibitor. The target therapy was restored at a reduced dose of 80 mg/day after 7 days of stop following electrocardiographic normalization. After 3 months of Gilteritinib, bone marrow aspiration confirmed morphological CR, full donor chimerism (99.96%), in absence of NPM1 positivity. Reduction of breast nodules was

| Table 1 | MRD and Chimeric Status after 1st allogeneic HSCT. |
|------------------|------------------|
| Timing after 1st HSCT (days) | % donor chimerism | NPM1 copies |
| +30 | 98.53 | 1.10 |
| +60 | 98.14 | 491 |
| +90 | 22.36 | 3191 |
| +120 | 45.05 | 0 |
| +150 | 70.7 | 229 |
| +180 | 62.8 | 267 |

NA: not available.

| Table 2 | MRD and Chimeric Status after 2nd allogeneic HSCT. |
|------------------|------------------|
| Timing after 2nd HSCT (days) | % donor chimerism | NPM1 copies |
| +30 | 99.64 | NA |
| +60 | 99.85 | 0.003 |
| +90 | 99.93 | 0.003 |
| +120 | 99.95 | 0.023 |
| +150 | 99.76 | 0 |
| +180 | 99.80 | 0 |
| +200 | 99.94 | 0.003 |
| +250 | 99.99 | 0.025 |
| +260 | 99.98 | 0.033 |
| +300 | 99.95 | NA |
| +360 | 99.96 | NA |
| +400 | 99.93 | NA |
| +460 | 99.86 | 0.001 |
| +500 | 99.57 | 0.001 |
| +560 | 99.67 | 0 |
| +600 | 99.70 | 0 |
| +660 | 99.80 | 0 |
| +700 | 99.80 | 0 |

Fig. 1. Breast presence of FLT3 ITD was documented by PCR and agarose gel electrophoresis (Kit LeukoStrat FLT3 Mutation Assay- Gel detection, Invivoscribe).
Fig. 2A. PT TC before treatment with Gilteritinib. B: PT TC after treatment with Gilteritinib.
documented by breast ultrasound and PET-CT [2,3].

Currently, almost 2 years after the 2nd allogeneic HSCT, the patient is alive in hematological and extramedullary CR with cutaneous GVHD responding to photo-apheresis and is still being treated with a FLT3 inhibitor at a dosage of 80 mg/day, as maintenance therapy. Fig. 2A and 2B respectively show the PT-TC breast images before and after Gilteritinib treatment.

3. Discussion

The second generation FLT3 inhibitors, such as Gilteritinib, have the advantage of being selective for FLT3 and therefore of acting in specific manner on cells expressing the mutation of this gene. The selectivity of these agents results in limited treatment-related adverse effects, increasing overall survival in patients with relapsed/refractory AML FLT3 in comparison to conventional chemotherapy. [3,4,5]. However, their use after allogeneic HSCT is still matter of debate. Recently, a randomized clinical trial (EURADRACT 2010–018, 539–16) assessed the efficacy of maintenance therapy with Sorafenib in the setting of FLT3+ AML who underwent allogeneic HSCT. This clinical trial showed a significant benefit in terms of overall survival and relapse free survival in the study arm versus the control group who received placebo [10,11]. Moreover, data about the use of TKI for extramedullary relapse of FLT3 AML after allogeneic HSCT are still very scarce [1,2,5].

In this context, we reported the case of a young patient affected by AML NPM1 and FLT3-ITD who underwent two allogeneic HSCT and who was treated with Gilteritinib for the 1st hematological and the second extramedullary relapse after the first and the second allogeneic procedure, respectively. In this single experience, treatment with Gilteritinib can be defined as manageable and safe with a low cardiac toxicity occurrence, although it was administered during GVHD. Worthy of note, the 2nd allogeneic HSCT was performed without immunosuppression in order to enhance the graft versus leukemia effect of the transplant procedure and this choice determined the onset of grade IV aGVHD followed by extensive cGVHD [5,9,10]. However, although a full donor chimerism and the persistent hematological CR after the second allograft, the occurrence of leukemic breast localization confirmed the possibility of blast cells escapement as mechanism of action for AML relapse, also in presence of aGVHD, underlying the potential dissociation between graft versus leukemia and host effect. In conclusion, this case report points out 4 main effects of Gilteritinib: 1) the potential utility of FLT3 inhibitors in patients who relapse after allogeneic transplant, 2) the efficacy on the extra-hematological relapse 3) the safe administration during GVHD 4) the persistent efficacy of the same FLT3 inhibitor in two different episodes of AML relapse after allogenic HSCT [9,10]. Further cases will be needed to establish the long-term efficacy of Gilteritinib in the treatment of extramedullary relapses after allogeneic HSCT and its possible impact on GVHD.

Declaration of Competing Interest

Authors have no relevant financial conflict of interest to declare.

Acknowledgement

We thank all our colleagues from AORN Cardarelli who provided insight and expertise that greatly assisted the patient.

References

[1] F.A. Perl, G. Martinelli, J.E. Cortes, et al., Gilteritinib or Chemotherapy for relapsed or refractory FLT3-mutated AML, N. Engl. J. Med. 381 (2019) 1728–1740.
[2] T. Kumode, S. Rai, H. Tanaka, J.L. Espinoza, et al., Targeted therapy for medullary and extramedullary recurrence of acute FLT3-ITD myeloid following allogeneic hematopoietic stem cell transplantation, Leuk. Res. Rep. (2020) 14.
[3] M. Kids, Y. Kuroda, M. Kido, Chishaki et al. Successful treatment with Gilteritinib for isolated extramedullary recurrence of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation, Int. J. Hematol. (2020).
[4] S. Yoshitaka, T. Ando, H. Ogawa, Extramedullary recurrence of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: an easily overlooked but significant relapse model, Biol. Blood Marrow Trans. 12 (18) (2012) 1800–1807.
[5] F. Ferrara, A. Picardi, Is outcome of older people with acute myeloid leukemia improving with new therapeutic approaches and stem cell transplantation? Exp. Rev. Hematol. (2020) https://doi.org/10.1080/17474086.2020.1715207.
[6] F. Buccisano, L. Maurillo, A. Piciocchi, et al., Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia, Bone Marrow Trans. 52 (2017) 473–475.
[7] A. Picardi, A. Lanti, L. Cadillo, et al., Platelet gel for treatment of mucocutaneous lesions related to graft-versus-host disease after allogeneic hematopoietic stem cell transplant, Transfusion 50 (2010) 501–506.
[8] A. Picardi, A.M. Ferraro, M. Miranda, Therapeutic efficiency of platelet gel for the treatment of oral ulcers related to chronic graft versus host disease after allogeneic hematopoietic stem cell transplantation, Oral. Implantol. (Rome) 4 (2012) 1974–5648.
[9] A. Burchert, G. Bug, L. Fritz, et al., Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-inter tandem duplication mutation (SORMAIN), J. Clin. Oncol. 38 (26) (2020) 2993–3002. Sep:10.
[10] P. Reville, Kadian TM Manteinance, Therapy in AML, Front. Oncol. 10 (2021) 1–10.